Toxicity Study Affirms Safety of Caralluma Fimbriata Satiety Ingredient
The six-month, chronic, oral toxicity rat study found no deaths or treatment-related toxicities of Caralluma fimbriata at three doses.
Herbal appetite-suppressant ingredient Caralluma fimbriata presented no toxicity concerns in a study recently published in the International Journal of Toxicology.
The six-month, chronic, oral toxicity rat study found no deaths or treatment-related toxicities of Caralluma fimbriata at three doses: 100, 300, and 1000 mg/kg body weight. The studies performed included two in vitro genotoxicity assays; a repeated-dose oral toxicity study; and a prenatal developmental study during which no external, visceral, or skeletal fetal abnormalities were observed up to the maximum dose tested.
“Together with its scientifically validated ability to reduce fat and suppress appetite, Caralluma fimbriata offers both safety and efficacy,” said Paul Clayton, PhD, chief scientific advisor at Gencor, an India-based ingredients supplier that supplies its Slimaluma brand of Caralluma fimbriata. The company says that two previous double-blind, placebo-controlled clinical trials found statistically significant decreases in waist circumference in experimental groups taking Caralluma fimbriata compared to placebo groups. Gencor’s Slimaluma is GRAS affirmed, kosher, halal, and can be supplied certified organic.
CRN NY State lawsuit update: Dispatch from SupplySide East 2024
April 18th 2024CRN's Steve Mister updates Nutritional Outlook about its ongoing litigation against NY State. The organization sued the state to prevent the enforcement of law that bans sale of weight management supplements to minors.
Microalgae extract supports metabolic health and bone mass during diet and exercise routine
April 11th 2024The extract from Microphyt, called PhaeOptim, was shown to complement weight management strategies that include diet and exercise by support bone mass, aerobic capacity, resting heart rate, and blood lipid profiles.
